Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Karyn A. Goodman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4576-6355; OpenAlex author ID A5054489256. Sources: OpenAlex.

Their work

Papers
39 (first author 5, last author 7)
Trials
0
Grants
0
Labs led
4
Collaborators
160
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers · 2014: none · 2015: 4 papers · 2016: 2 papers · 2017: 5 papers · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 7 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers · 2026: 1 paper

Papers 39

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  3. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  4. Adjuvant Radiation for Resected Pancreatic Cancer: Historical Review and Current State. Co-author DOI 10.1016/j.semradonc.2025.07.009↗
  5. Patterns of care in pancreatic cancer radiotherapy: impact of facility volume on outcomes. Last author DOI 10.3389/fonc.2025.1654223↗
  6. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Co-author DOI 10.1016/j.prro.2024.06.004↗
  7. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2023.03.036↗
  8. Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-2767↗
  9. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleoti… Co-author DOI 10.1007/s00262-020-02701-w↗
  10. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreati… Last author DOI 10.1016/j.hpb.2020.11.004↗
  11. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.11.017↗
  12. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Co-author DOI 10.1093/bjs/znab092↗
  13. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3892↗
  14. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Last author DOI 10.1200/jco.21.01220↗
  15. Longitudinal Monitoring of Simulated Interstitial Fluid Pressure for Pancreatic Ductal Adenocarcinoma Patients Treated with Stereotactic Body Radiotherapy. Co-author DOI 10.3390/cancers13174319↗
  16. Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1001/jamasurg.2019.5464↗
  17. Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminar… Co-author DOI 10.18383/j.tom.2020.00015↗
  18. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2019.06.016↗
  19. Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter? Co-author DOI 10.1158/1078-0432.ccr-18-3042↗
  20. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. First author DOI 10.1186/s13014-019-1277-1↗
  21. The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. Co-author DOI 10.21037/jgo.2019.01.19↗
  22. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pan… Co-author DOI 10.1002/jso.25004↗
  23. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. Last author DOI 10.1080/0284186x.2016.1245862↗
  24. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Co-author DOI 10.1080/0284186x.2017.1342863↗
  25. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000370↗
  26. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Last author DOI 10.1097/mpa.0000000000000876↗
  27. Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities. First author DOI 10.21037/cco.2017.06.12↗
  28. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cance… Co-author DOI 10.1016/j.prro.2016.05.005↗
  29. Stereotactic Body Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1097/ppo.0000000000000206↗
  30. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocar… Co-author DOI 10.1002/cncr.29161↗
  31. Pancreatic cancer and SBRT: A new potential option? First author DOI 10.1016/j.rpor.2015.05.008↗
  32. Erratum to: "Pancreatic cancer and SBRT: A new potential option?" [Rep. Pract. Oncol. Radiother. 20 (2015) 377-384]. First author DOI 10.1016/j.rpor.2015.10.001↗
  33. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4647-4↗
  34. Role of radiation therapy in the management of pancreatic cancer. Co-author DOI 10.1002/jso.23137↗
  35. A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarci… Co-author DOI 10.1016/j.prro.2013.01.016↗
  36. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-match… Co-author DOI 10.1111/hpb.12033↗
  37. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. First author DOI 10.1016/j.ijrobp.2011.11.050↗
  38. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Co-author DOI 10.1245/s10434-011-2156-7↗
  39. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.05.006↗

Closest collaborators

The 25 strongest of 160 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marsha Reyngold · 7 shared papers, 2017–2026 · strength 1.03
  2. Joseph M. Herman · 9 shared papers, 2013–2025 · strength 0.95
  3. William Adrian Hall · 6 shared papers, 2019–2025 · strength 0.91
  4. Amol Kumar Narang · 4 shared papers, 2021–2026 · strength 0.71
  5. Daniel Tandel Chang · 7 shared papers, 2011–2026 · strength 0.65
  6. Richard David Schulick · 6 shared papers, 2018–2022 · strength 0.60
  7. Michael David Chuong · 3 shared papers, 2024–2026 · strength 0.59
  8. Wells A. Messersmith · 6 shared papers, 2017–2022 · strength 0.59
  9. Carla Hajj · 6 shared papers, 2013–2023 · strength 0.57
  10. Sana D. Karam · 5 shared papers, 2021–2023 · strength 0.55
  11. Eileen Mary O'Reilly · 8 shared papers, 2012–2025 · strength 0.54
  12. Marco Del Chiaro · 5 shared papers, 2021–2022 · strength 0.52
  13. Terence Marques Williams · 3 shared papers, 2020–2025 · strength 0.52
  14. Christopher H. Crane · 4 shared papers, 2017–2024 · strength 0.50
  15. Leila T. Tchelebi · 2 shared papers, 2025 · strength 0.47
  16. Manisha Palta · 4 shared papers, 2019–2025 · strength 0.46
  17. Richard Kinh Gian · 4 shared papers, 2015–2023 · strength 0.44
  18. Adam Christopher Mueller · 4 shared papers, 2021–2022 · strength 0.43
  19. Michael Frederick Bassetti · 2 shared papers, 2025–2026 · strength 0.41
  20. Nina Niu Sanford · 2 shared papers, 2025–2026 · strength 0.41
  21. Amita Shukla‐Dave · 3 shared papers, 2020–2023 · strength 0.40
  22. Albert C. Koong · 7 shared papers, 2011–2021 · strength 0.38
  23. Ross Allen Abrams · 3 shared papers, 2012–2025 · strength 0.38
  24. Arvind Rajan · 1 shared paper, 2025 · strength 0.37
  25. Elizabeth Gleeson · 1 shared paper, 2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.